GlassScriptPhysician profile
Alison M Munchak
NPI 1750817375
$22,000.94
in general payments reported to CMS, 2019-2025
30 companies · $3,056 in 2025
The $3,056 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,456 · 2022: $4,573 · 2023: $5,541 · 2024: $5,375 · 2025: $3,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,619.08 |
| Education | $352.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,080.78 | 2021-2025 | |
| Amgen INC. | $2,911.58 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $2,058.24 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,441.95 | 2021-2025 | |
| Ucb, INC. | $1,238.88 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,020.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,018.90 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $861.13 | 2021-2025 | Taltz |
| Glaxosmithkline, LLC. | $809.85 | 2021-2025 | Benlysta, Nucala |
| Genzyme Corporation | $580.01 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $456.60 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $403.01 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $364.56 | 2021-2024 | Lupkynis |
| Organon LLC | $279.34 | 2023-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $201.28 | 2024-2025 | Orencia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $200.33 | 2022-2023 | Tymlos |
| Sobi, INC | $199.93 | 2021-2025 | |
| Horizon Therapeutics Plc | $182.02 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $106.19 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.41 | 2021-2025 | Ofev |
| Kyowa Kirin, INC. | $75.08 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $71.83 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $66.98 | 2022-2025 | Zilretta |
| Fresenius Kabi USA, LLC | $63.21 | 2023-2024 | Idacio |
| Bioventus LLC | $58.68 | 2022-2024 | Durolane |
| Novo Nordisk INC | $53.47 | 2022-2024 | Wegovy |
| Pacira Therapeutics, INC. | $46.78 | 2021 | |
| Tersera Therapeutics LLC | $20.83 | 2024 | Quzyttir |
| Sandoz INC. | $14.83 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Munchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.